Acne affects 85% of teenagers, over 42% of men, and just over half of all women between the ages of 20 and 30 years. Much of it is thought to be from the 5a-reduction of testosterone into Dihydrotestosterone, contributing to sebum production. This has lead to steroid users experimenting with topical anti-androgens such as Ketoconazole (under the brand name Nizoral) as a method of controlling androgen-induced acne. It appears that the pharmaceutical world has finally caught up with steroid users, and is in the stages of releasing a topical anti-androgen for the treatment of acne.

The product is an androgen receptor (AR) degradation enhancer (ARD enhancers), which functions thhrough reduction of the androgen receptor and androgen function in sebaceous glands, thereby halting the onset of acne hormonally.

A topical cream under the name ASC-J9 has shown success in acne reduction and has been shown to be safe in the first two stages of clinical trials.